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Abstract
Colorectal cancer (CRC) accounts for ~9% of all cancers in the Veteran population, a fact which has focused a great deal of 
the attention of the VA’s research and development efforts. A field-based meeting of CRC experts was convened to discuss 
both challenges and opportunities in precision medicine for CRC. This group, designated as the VA Colorectal Cancer Cell-
genomics Consortium (VA4C), discussed advances in CRC biology, biomarkers, and imaging for early detection and preven-
tion. There was also a discussion of precision treatment involving fluorescence-guided surgery, targeted chemotherapies and 
immunotherapies, and personalized cancer treatment approaches. The overarching goal was to identify modalities that might 
ultimately lead to personalized cancer diagnosis and treatment. This review summarizes the findings of this VA field-based 
meeting, in which much of the current knowledge on CRC prescreening and treatment was discussed. It was concluded that 
there is a need and an opportunity to identify new targets for both the prevention of CRC and the development of effective 
therapies for advanced disease. Also, developing methods integrating genomic testing with tumoroid-based clinical drug 
response might lead to more accurate diagnosis and prognostication and more effective personalized treatment of CRC.
Keywords Biomarkers · Cancer stem cells · Clinical drug response · Colorectal cancer · FiSS · Genomic testing · Next 
generation sequencing · Precision Oncology Program (POP) · Tumoroids
Introduction
Colorectal cancer (CRC) is the second most common cause 
of cancer-related deaths in the USA with an estimated 5% 
lifetime risk [1]. Another 3% of individuals diagnosed with 
CRC have a high-risk hereditary cancer syndrome such as 
Lynch syndrome. In recent years, a major emphasis has been 
placed on screening of conventional adenomatous and ser-
rated polyps with the intention of removing them prior to 
their progression to CRC. The serrated polyp has been rec-
ognized as a progenitor of 15–30% of all CRCs. Technologi-
cal advancements in CRC screening procedures and modali-
ties, such as fecal immunochemical test (FIT), air contrast 
barium enema, and colonoscopy, have led to a decrease in 
mortality from CRC since the mid-1980s [1]. Despite these 
screening tools, only 40% of CRCs are diagnosed at an early 
stage (I or II) [2]. This is due in part to a lack of patient com-
pliance, limited access to screening colonoscopy, and the 
low sensitivity/specificity of more commonly used tests such 
as FIT [2]. Furthermore, a “one drug fits all” cancer treat-
ment approach has been unsuccessful in effectively reducing 
cancer deaths. For these reasons, there is an urgent need to 
identify new strategies for the prevention of CRC as well 
as the development of effective therapeutics for advanced 
disease.
Specifically, the US Veteran population represents 3% of 
all cancer patients in the USA and CRC accounts for ~9% 
of all cancers among Veterans [4]. This is because a large 
proportion of Veterans receiving care under Veterans Health 
Administration (VHA) have poor health, multiple comorbid-
ities, and lower income [3]. Further, the incidence of cancer 
among Veterans is likely to increase with the aging popu-
lation, an increase in military personnel, and an increase 
in Veterans seeking health care in VHA [4]. VHA has 
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supported a Precision Oncology Program (POP) that uses 
multi-gene, next-generation sequencing (NGS) panels for 
patients diagnosed with Stage III or IV CRC, with an intent 
to provide precision cancer treatment (PCTx). These panels 
screen for ~ 200 genes, cost about $1500 per panel, have a 
turnaround time of about 2 weeks, and are not validated 
for PCTx use. Also, since genomic testing only provides a 
predictive approach, several tumor spheroid culture systems 
have been examined for their potential use in PCTx, but this 
technology also has several critical barriers. Thus, there is 
a need to integrate genomics and cell-based approaches, 
referred to as “cell-genomics,” to accurately diagnose, prog-
nosticate, and treat gastrointestinal malignancies including 
pancreatic and CRCs. To this end, in a VA R&D supported 
field-based meeting, a panel of CRC experts met to review 
research advances on the biology, biomarkers, and treatment 
of CRC. The panel discussed the state-of-the-art science, 
challenges, and opportunities and pragmatically established 
a “VA Colorectal Cancer Cell-genomics Consortium” 
(VA4C) with the goal of fostering multi-site collaborative 
studies aimed at early detection, prevention, and diagnosis as 
well as novel treatments for CRC. This review summarizes 
these discussions on the latest developments in biology and 
biomarkers to individualize diagnostics and prognostication 
and precision oncology approaches, and charts future col-
laborative research directions.
Precision Diagnostics and Prognostics 
for CRC 
Advances in Biology, Biomarkers, and Imaging 
for Early Detection of CRCs
To date the principal modalities for identifying early-stage 
CRCs have been through use of screening colonoscopy or 
fecal-based methods such as FIT. The rationale for this 
approach is to identify either polyps (precancerous) or 
early-stage CRCs before they develop into lethal tumors. 
Early-stage CRC is curable with surgical treatment, whereas 
advanced or metastatic disease may only be treated to pro-
long survival without curative intent [5]. The traditional par-
adigm is that sporadic CRC progresses in a stepwise fashion 
from normal epithelium, to aberrant crypt foci, to low-grade 
then high-grade adenomas and ultimately to adenocarcinoma 
which may then metastasize to other organs. This pattern 
of tumor progression was first identified by Vogelstein and 
colleagues some 30 years ago [6]. It is now known that can-
cer cell heterogeneity and other factors can modulate this 
progression. For example, recent studies suggest that CRCs 
originating from different locations may have different meta-
static targets, for example, colon cancer spreads primarily 
to liver, whereas rectal cancer spreads primarily to lung 
[7]. Moreover, early in tumorigenesis, some cells within 
the primary tumor already possess the ability to invade and 
seed distant organs [8]. Such cells have acquired mesen-
chymal traits through the epithelial-to-mesenchymal tran-
sition (EMT). EMT is defined by a variety of genetic and 
morphological changes, which allow cells to invade normal 
colon epithelium, vascular endothelium, and eventually the 
parenchyma of target organs. Recent work indicates that the 
genetic signatures identifying EMT may also be cell context-
dependent [9]. Metastatic cell deposits may grow slowly or 
lie dormant until circulating and stroma-dependent factors 
stimulate their arousal and growth.
An important anatomical factor very specific to CRC is 
the recently identified “serrated polyp-neoplasia” pathway 
[10–12]. Sessile serrated adenoma/polyps (SSA/Ps), estab-
lished precursors of CRC, exhibit microsatellite instability 
(MSI) and account for approximately 15–30% of sporadic 
CRCs [13]. SSA/Ps are predominantly located in the right/
proximal colon and observed in “interval cancers” occurring 
within a short time after a screening procedure (2–6% of 
all CRCs) [14, 15]. Serrated polyps are characterized by a 
variety of histologic features including irregular distribution 
of crypts, dilatation of crypt bases, serration at crypt bases, 
branched crypts, horizontal extension of crypt bases, dysma-
turation of crypts, and herniation of crypts through the mus-
cularis mucosae [16]. According to the American Gastroen-
terology Association criteria, even one crypt showing any 
of the above characteristics is sufficient to diagnosis SSA/P. 
Approximately 17.6% of SSA/Ps (> 2 cm) show residual 
adenomatous tissues when reexamined [17]. Unlike other 
adenomatous polyps, SSA/Ps are characterized by mutations 
in the BRAF proto-oncogene that causes the development of 
polyps. Hyper-methylation of CpG islands in the promoter 
regions of tumor suppressor genes, including MLH1, leads 
to a decrease in tumor suppression and an increase in spo-
radic MSI [10, 18–21]. Because benign hyperplastic polyps 
(HPs) and SSA/Ps have a different risk of developing into 
malignant disease, their accurate classification is critical 
for making clinical decisions (e.g., surveillance intervals, 
intervention). Understanding these complex processes and 
testing all prognostic and therapeutic measures in animal 
models before proceeding to clinical trials is challenging. 
It is noteworthy that although colonoscopic screening and 
polypectomy have led to a decline in advanced CRC, its 
utility for differentiating SSA/Ps from HPs has not yet been 
realized.
Genetic and Epigenetic CRC Biomarkers
The multistep process of CRC development is associated 
with the accumulation of genetic and epigenetic altera-
tions in epithelial cells via distinct molecular pathways, 
including the common “adenoma-carcinoma” pathway as 
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well as the recently identified “serrated polyp-neoplasia” 
pathway [6–8]. Hence, identifying these CRC molecular 
markers, i.e., biomarkers, is key to early detection, staging, 
and assessment of therapeutic efficacy, as reviewed recently 
[22]. Whereas current guidelines recommend surgery alone 
for Stage I and adjuvant chemotherapy for Stage III can-
cers, the appropriate treatment for Stage II cancers, which 
have breached the colon wall but not invaded lymph nodes 
or other organs, is uncertain. Although it is proposed that 
molecular biomarker panels, including genetic, epigenetic, 
protein and carbohydrate-based markers, may identify Stage 
II cancers that warrant aggressive treatment after surgical 
resection [23], none have been validated prospectively.
Circulating tumor DNA and RNA-based biomarkers 
offer high specificity and are ideal as predictive biomark-
ers for monitoring the response to chemotherapy as well 
as tumor progression, as reviewed recently [24]. However, 
due to low DNA yields and low mutational burden, they are 
inadequate for diagnosis. Cell-free microRNAs (miRNAs) 
and small non-coding RNAs (ncRNAs) are now emerging as 
noninvasive and highly sensitive biomarkers, but specificity 
remains a concern. For these reasons, large-scale prospective 
clinical studies aimed at carefully evaluating the sensitivity 
and specificity of these biomarkers are needed before their 
adoption to clinical practice.
Hereditary cancer syndromes have provided powerful 
insights into our understanding of somatic mutations pre-
sent in sporadic cancers, as well as implicated cell signal-
ing pathways [20–24]. One clear example is the identifica-
tion of germline, inactivating mutations in the APC gene, 
which encodes a 300-kD wnt pathway adaptor protein [23]. 
Although germline mutations in APC are responsible for 
familial adenomatous polyposis (FAP), a rare condition 
affecting about 1 in 7000 individuals in the USA, somatic 
mutations in the APC gene are present in more than 70% of 
colonic adenomatous polyps and carcinomas [24]. Heredi-
tary non-polyposis colon cancer (HNPCC), or Lynch syn-
drome, involves a germline mutation in a DNA mismatch 
repair (MMR) genes, leading to defective DNA repair. 
Recent studies identifying inactivation of TGF-β signal-
ing through loss of the Smad3 adaptor ß-2 spectrin could 
potentially provide new insights into CRC development 
from stem-like tumor-initiating cells (STICs) for targeted 
chemoprevention.
Further, genome-wide association studies (GWAS) have 
identified numerous genetic loci that are associated with 
CRC, but hereditability remains unknown. More than 40 
low-penetrant polymorphic variants are reported [25]. More 
recently in a Finnish cohort, a single-nucleotide polymor-
phism (SNP) rs992157 at chromosome 2q35 intronic to 
PNKD and TMBIMI was found to be associated with CRC 
[26]. Genome-wide alterations in DNA methylation influ-
ence gene expression resulting in altered aberrant crypt foci, 
an early precursor of CRC [27]. Recently, single-cell RNA 
sequencing (e.g., GemCode technology 10 × Genomics, San 
Francisco, CA) has permitted an assessment of transcrip-
tional events that may be important in the development of 
cancers and could potentially predict therapeutics. In addi-
tion to genomic profiling approaches, depending upon the 
molecule of interest, several additional “omics” approaches 
are being utilized, including proteomics, metabolomics, lipid-
omics (chloroform/methanol), glycomics (glycoprotein isola-
tion), and peptidomics.
TGF‑β Receptor and SMAD Gene Mutations 
in Gastrointestinal/CRC 
In normal and premalignant cells, TGF-β enforces homeo-
stasis and suppresses tumor progression through tumor-sup-
pressive effects on the stroma. Current data strongly support 
TGF-β signaling as a suppressor of early CRCs [28, 29]. In 
advanced disease, metastatic CRCs escape the tumor sup-
pressor effects of TGF-β signaling by becoming resistant to 
TGF-β-induced growth inhibition [30]. Inactivating muta-
tions in the TGFBR2 gene occur in most human CRC and 
gastric carcinomas that demonstrate MSI [31]. The TGF-β 
signaling network is also disrupted in cancer by mutations 
in Smad4, which occur in more than 30% of CRCs [32, 33]. 
Smad-deficient mice display phenotypes that suggest a tumor 
suppressor role for the Smads [34]. When mice with one 
mutated APC allele are crossed with heterozygous Smad4 
mice, the compound heterozygotes develop larger polyps that 
can progress into malignant adenocarcinomas [35]. Although 
fewer Smad3 mutations have been found in human cancers, 
mice with a Smad3 homozygous deletion develop aggres-
sive CRC at an early age in a manner that seems to be highly 
dependent on the genetic background of the mice.
Cross talk between CEA, TGF‑β signaling, and STAT3
Figure 1 depicts cross talk between carcinoembryonic anti-
gen (CEA), TGF-β signaling, and STAT3. Advanced CRC is 
associated with high levels of circulating CEA and a dismal 
survival; the elevated levels of CEA are especially associ-
ated with Stage IV cancers. Consequently, there is a need 
to identify new targets for both the prevention of CRC as 
well as the development of novel therapies for advanced 
cancer. CEA (also known as CEACAM5) is one of the few 
biomarkers approved by the U.S. Food and Drug Adminis-
tration (FDA) for CRC [36]. TCGA studies have validated 
that elevated CEA levels and disruption of TGF-β signaling 
are observed in over 80% of right-sided CRCs [37]. Activa-
tion of STAT3 is also observed in this subgroup of patients. 
TGF-β induces the secretion of CEA in a dose-dependent 
manner [38]. Given the importance of CEA, TGF-β, and 
STAT3 signaling pathways in CRC tumorigenesis, cross talk 
1126 Digestive Diseases and Sciences (2018) 63:1123–1138
1 3
between these pathways is a focus of investigation. CEA and 
CEACAM6 are known Smad3 target genes. An important 
direction for the future is designing studies that delineate the 
molecular mechanisms underlying the cross talk between 
CEA and the TGF-β and STAT3 signaling pathways during 
CRC development.
Mucins as Biomarkers for CRC Early Detection 
and Prognosis
Several studies showed moderate to high inter-observer 
disagreement between pathologists in the histologic differ-
entiation of SSA/Ps (highly malignant) and HPs (benign) 
[21, 39–46]. Considering this variability, studies have 
focused on identifying molecular markers for distinguishing 
between these two entities. For example, MUC5AC, TFF1, 
and Annexin A10 have emerged as potential markers for 
differentiating benign polyps from SSA/P [47, 48]. Aberrant 
changes in the expression, localization, and glycosylation 
of colonic mucin have been observed in very early stages of 
colon cancer. SSA/Ps exhibit an elevated expression of trans-
membrane mucin MUC17 and secreted mucin MUC5AC in 
comparison to HP [49]. Notably, in conjunction with these 
expressional changes, distinct differences were also observed 
among the studied polyp groups in MUC5AC and MUC4 
localization. This signifies the ability of these markers to 
discriminate benign HP from SSA/P polyp subtypes. In mul-
tivariate regression models in conjunction with ROC curve 
analyses, the combination of MUC17/MUC5AC effectively 
discriminated SSA/Ps from HP [49]. The trio (CA 19-9, 
MUC17, and MUC5AC) emerged as a combined panel for 
discriminating polyp subtypes and thus accurately classify-
ing colorectal polyps. Based on the lack of clear tools to 
identify SSA/Ps, histologic markers can aid in improving 
Fig. 1  Schematics of cross talk 
between CEA, TGF-β signaling, 
and IL6-STAT3 pathway
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the differentiation of SSA/Ps from benign polyp subtypes. 
Due to difficulties in their diagnosis by endoscopists, their 
inter-observer variability among pathologists, and their 
highly malignant nature, a means of identifying SSA/Ps is 
central to the improved detection and timely treatment of 
CRC. There is a broad consensus that future studies should 
focus on identifying alternative molecular markers that can 
more successfully achieve these goals.
Biomarkers for Colon Cancer Dissemination
One novel approach to stratify the malignant potential of 
CRC is to identify cancer cells with distinct invasive poten-
tial at the tumor “front,” namely the interface between tumor 
and normal tissue. Nuclear accumulation of β-catenin dis-
tinguishes the cells at the “front” from those closer to the 
tumor core [50]. This is consistent with observations that 
cells tend to invade in clusters, not as individuals [9]; these 
cells likely share attributes that predispose them to behave as 
an aggressive unit. Cell clusters at the tumor front are more 
likely to co-overexpress M3 muscarinic receptors (M3R) 
and matrix metalloproteinase-1 (MMP1) within cytoplas-
mic vesicles [51]. This is potentially important since M3R 
activation robustly induces expression of MMP1, a secreted 
collagenase that promotes colon cancer invasion [52–54]. 
Validating the use of such histochemical tests in formalin-
fixed paraffin-embedded tissues may yield an efficient and 
economical way to identify those Stage II cancers that 
require more aggressive therapy.
Histopathology with Neuroendocrine Tumor (NET) 
Stains Identifies Neuroendocrine Features of CRC 
A subset of adenocarcinomas and adenomas possess neuroen-
docrine features [55]. Neuroendocrine cells possess bioactive 
amines and peptides that may have an important role in pro-
moting the growth of transformed cells such as those within 
adenocarcinomas, as has been demonstrated with peptides 
such as PACAP [56]. The expression of receptors on CRCs 
can differentially couple to intracellular signaling molecules 
that promote proliferation [57]. A recent study identified neu-
roendocrine features in up to one-third of 40 patients with 
CRC (unpublished data); assays of chromogranin A and neu-
ron-specific enolase were performed (Fig. 2). The presence of 
neuroendocrine features may suggest a stem cell component 
or portend a more aggressive tumor state. Neuroendocrine 
features may also suggest different chemotherapeutic or bio-
logic strategies in advanced-stage CRC.
Role of Microbiome in CRCs
Well-established risk factors for colorectal adenomas and 
cancer include: a personal or family history of CRC or pol-
yps; an inherited condition that predisposes to colon polyps 
and cancer; inflammatory bowel disease (e.g., Crohn’s dis-
ease or ulcerative colitis); obesity; type 2 diabetes; heavy 
alcohol use; a diet high in red meat and processed meats; 
smoking; and physical inactivity. Additional risk factors that 
have been described include fatty liver [58], hepatitis C [59], 
and Agent Orange exposure [60]; the latter is very relevant 
to Vietnam Veterans. Modifying known dietary and lifestyle 
risk factors and chemoprevention with aspirin and nonsteroi-
dal anti-inflammatory drug (NSAID) use are associated with 
reduced risk for colon polyps and CRC [61]. In relation to 
the role of the diet and intestinal microbiome in CRC patho-
genesis, the microbiome of subjects consuming a Western 
diet (WD) was compared to that of subjects consuming a 
high-protein diet (HPD) [62] (Fig. 3a, b). There was a highly 
significant difference in composition by weighted UniFrac 
analysis (p < 10−5) (Fig. 3b). At the genus level, the HPD 
microbiome was characterized by expansion of Akkermansia, 
Ruminococcus, and Bacteroides and depletion of Lactobacil-
lus and Turicibacter (Fig. 3c). The HPD group had increased 
abundance of 114 operational taxonomic units (OTUs) 
selected at 97% similarity (corresponding approximately to 
Fig. 2  a NET features by H&E staining in colorectal adenocarcinoma specimen. b NET features by chromogranin A immunohistochemistry 
staining in colorectal adenocarcinoma specimen. Unpublished data
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species) at a threshold of q < 0.05 (representing significance 
adjusted for multiple hypothesis testing).
Of these, only Akkermansia mucinophila (q = 0.008) and 
an unclassified Clostridiales (q = 0.04) had a statistically 
significant inverse correlation with fat mass after adjust-
ment for diet [62]. Fusobacterium enrichment is associated 
with specific molecular subsets of CRCs, suggesting that 
there is a potential pathogenic role in the development of 
CRC [63]. Furthermore, it has also been shown that envi-
ronmental pollutants may affect the microbiome, such as was 
observed with ultrafine particles [64]. Whether ultrafine par-
ticles affect the steps involved in colon cancer pathogenesis 
remains to be investigated.
Precision Imaging for Prevention of CRCs
Screening colonoscopy has emerged as perhaps the most 
effective lifesaving intervention against CRC to date. Pooled 
analysis of numerous large observational studies indicates that 
systematic removal of all visualized polyps including adeno-
matous and serrated polyps [43, 65] at colonoscopy decreases 
proximal and distal CRC incidence and mortality by > 60% 
[2]. Currently, a VA clinical trial (50,000-subject, prospec-
tive randomized controlled study) is underway (Cooperative 
Studies Program #577) to assess screening colonoscopy ver-
sus FIT for reducing CRC deaths. While cancer death rates 
in persons older than 50 years are now declining, likely due 
to the adoption of screening programs, recent data indicate 
that age-specific CRC incidence and mortality are actually 
rising in those < 50 years of age. Colonoscopy has not been 
fully protective due to several uncontrollable factors including 
missed polyps, operator factors [66–69], and an inability to 
detect atypical [70] serrated polyps and poorly visualized flat 
neoplasms [71]. Thus, colonoscopy can benefit from assistive 
technologies that improve the neoplastic polyp detection rate as 
a primary performance benchmark [72]. To this end, standard 
colonoscopy has undergone recent enhancements to improve 
detection of more subtle lesions and has been supplemented 
with other technologies that provide “real-time histology” to 
enable selective removal [73–75]. Clinical trials, however, 
have shown that both high definition colonoscopy and dye 
spray chromoendoscopy only marginally improve neoplas-
tic polyp detection [76, 77]. Using retrograde and ultra-wide 
angle camera systems that reveal surface area between folds 
can improve neoplastic polyp detection by 23–70% [78, 79]. 
Selective wavelength imaging and transparent cap-assisted 
colonoscopy have had mixed results [80, 81]. Thus, despite 
some improvements there remains a major unmet need in the 
ability to detect and remove atypical and serrated polyps.
CRC: Advances in Precision Surgery 
and Treatment
Although surgical resection is the mainstay of treatment in 
early-stage CRC, incomplete removal of tumors leads to 
local or widely metastatic disease which is resistant to con-
ventional chemotherapeutics. For patients whose disease has 
progressed to metastatic CRC, molecular profiling may shed 
light on why various treatments fail. The discussions in this 
section focus first on advancing CRC precision treatment 
through increased precision in CRC surgery. Secondarily it 
reviews the state of the art in targeted chemotherapies.
Fluorescence‑Guided Surgery for CRC 
Surgical resection for CRC has the greatest potential for 
cure. Since the application of complete mesocolic exci-
sion for colon cancer surgery, local 5-year recurrence rates 
have decreased [82]. Furthermore, achieving negative 
Fig. 3  A high-protein diet induces fat loss and an altered intestinal 
microbiome in rats with Western diet-induced obesity. a Body fat 
mass of rats kept on a WD or switched to a HPD. Age-matched con-
trol rats on a ND are shown for comparison. **p < 0.01 b Principal 
coordinates analysis (PCoA) of the cecal luminal microbiome colored 
by diet. P value across groups calculated using Adonis. c Mean abun-
dance of common genera. Some reads were identified only at the fam-
ily (f) or order (o) level
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microscopic margins and complete resection of metastatic 
tumor (R0 resection) can significantly improve 5-year sur-
vival rates [83–87]. Despite achieving R0 resection rates 
in patients with CRC, local and distant recurrence has still 
been reported to be as high as 34% [84, 88, 89]. Further-
more, the prognosis of patients with local recurrence is poor 
[90]. Real-time, reliable imaging to detect positive surgical 
margins at the time of surgery would improve outcomes. 
Emerging techniques are revolutionizing the performance 
of cancer surgery [91]. Intraoperative fluorescence imag-
ing, or fluorescence-guided surgery (FGS), can provide high 
fidelity tumor visualization for localization, resection, and 
margin confirmation [92]. Thus, targeted fluorescent labe-
ling of cancer cells may change the way we find and treat 
cancer [93, 94].
FGS combines advanced imaging platforms with targeted 
fluorescent agents to improve their intraoperative detection 
[95]. One technique is to covalently bind organic dye to a 
monoclonal antibody which labels a known tumor-specific 
antigen [91]. One such tumor biomarker is anti-CEA anti-
bodies which label human CRC in murine models [92, 
96–98] (Fig. 4). Mouse and chimeric (mouse/human) CEA 
antibodies, conjugated to fluorescent dyes, are capable of 
enhancing visualization of submillimeter tumor deposits 
[92] and aiding with FGS [99–101]. In an effort to improve 
therapeutic efficacy in the clinic, Yazaki et al. [102] human-
ized the murine anti-CEA T84.66 antibody with structurally 
similar “human” segments through a technique known as 
complementary determining region (CDR) grafting. This 
humanized anti-CEA antibody is currently used in clini-
cal trials for PET imaging of CRC. In Europe, this tech-
nique was recently applied in clinical trials to localize CRC 
using SGM-101, an antibody-dye conjugate in which the 
fluorochrome BM104 is coupled to a chimeric monoclonal 
antibody against CEA [103]. Other fluorophore-conjugated 
antibodies to tumor-specific antigens such as insulin-like 
growth factor-1 receptor have been used in preclinical FGS 
for colon cancer [104]. In addition, viral vectors such as ade-
novirus and herpes virus can be used to deliver fluorescent 
proteins to cancer cells [105]. Activatable cell-penetrating 
peptides have been engineered to highlight tumors based 
on enzymatic cleavage of peptidases [106]. Indocyanine 
green (ICG), used clinically to define liver tumor margins, 
tissue perfusion, and biliary anatomy, has been shown to 
reduce leak rates after low anterior resection for CRC [107]. 
Thus, the use of FGS as a surgical guide has the potential to 
increase both survival and quality of life for patients [108]. 
FGS has great potential for a broad range of clinical applica-
tions, including in CRC.
Targeted Chemotherapies
Targeted therapies have recently been developed to join tra-
ditional therapeutic approaches to CRC including surgery, 
chemotherapy, and radiotherapy [109]. Targeted chemo-
therapy may be used for neoadjuvant treatment or adjuvant 
treatment. For advanced cancers that have spread to other 
organs, such as the liver, chemo can also be used to help 
shrink tumors and relieve symptoms. Although it is not 
likely to cure the cancer, it often prolongs life. Common 
drugs used for CRC include: 5-fluorouracil (5-FU), often 
given with leucovorin (also called folinic acid) or levo-leu-
covorin; capecitabine (Xeloda tablets) metabolized to 5-FU 
in tumors [110]; irinotecan (Camptosar); and a combination 
tablet containing oxaliplatin (Eloxatin) and trifluridine and 
tipiracil (Lonsurf).
About 85% of all sporadic CRCs occur due to chromo-
somal instability, and ~ 15% of all CRCs are caused by vari-
ous deficiencies in the DNA mismatch repair system. In the 
order of decreasing frequencies, TP53, KRAS, PIK3CA, 
BRAF, and PTEN are among the most commonly altered 
genes in CRC [111]. TP53 was the most commonly mutated 
gene, affecting 17/24 cell lines; hyperactivating KRAS muta-
tions were found in 15 cancer cell lines of which five were 
Fig. 4  Labeling of orthotopic human colon tumors in nude mice with 
fluorophore-conjugated chimeric anti-CEA antibodies. Panel A shows 
bright-field image of an orthotopic colon tumor (white arrow) and 
panel B shows the bright fluorescence of the tumor 48 h after labe-
ling the fluorophore chimeric anti-CEA antibodies. The absence of 
any fluorescence signal after fluorescence-guided surgery in panel C 
indicates a complete resection
1130 Digestive Diseases and Sciences (2018) 63:1123–1138
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homozygous, and BRAF mutations were found in another 
five cell lines.
Several cutting-edge biological modalities are under 
investigation. Mannosylated liposomes have been used to 
improve cell uptake and tumor inhibition rate [112]. This was 
shown without increase in toxicity. Thus, Patras et al. [113] 
have shown the effects of liposomal paclitaxel encapsu-
lated in long-circulating liposomes together with liposomal 
prednisolone phosphate to be superior in anti-tumor activ-
ity mainly related to anti-angiogenic and anti-inflammatory 
effects. Attempts have been made to detail the functional 
pathways microRNA array, and considerable knowledge 
has been accumulated [114]. Yao et al. [115] have shown 
the importance of microRNA-215 as a tumor suppressor in 
colon cancer, which paradoxically acts as oncogene in breast 
cancer, and have proposed this to be a novel therapeutic 
target. However, knowledge of several microRNAs is very 
limited in terms of their targeted genes [113, 114]. Zheng 
et al. studied the effects of caudal type homeobox (CDX2) 
and human telomerase reverse transcriptase (hTERT) [115]. 
hTERT and loss of CDX2 have been associated with colon 
cancer in humans. In their elegant experiment, they showed 
over-expression of CDX2 is associated with suppression of 
colon cancer progression [116]. Finally, as stated before, 
TGF-β has also been implicated in treatment of metastatic 
colon cancer [117].
Immunotherapies for CRC 
Immune surveillance is a key mechanism to protect against 
malignancy. Successful CRC immune surveillance relies 
on the effective function of antigen-presenting cells and T 
cells. It is now evident that this inadequate function of host 
immune system is due to suppressive factors like myeloid-
derived suppressor cells (MDSCs). It is one of the major 
mechanisms of tumor escape from immune control as 
well as an important factor limiting the success of cancer 
immunotherapy. MDSCs play an important role in tumor 
non-responsiveness by suppressing antigen-specific T cell 
responses [118–121]. These cells take up antigen delivered 
by vaccination, present it to activated T cells, and thereby 
inhibit the same antigen-specific T cells that the vaccina-
tion strategy is aiming to activate. Cancer patients or tumor-
bearing mice have a considerable number of MDSCs, which 
cause even the most effective antigen-delivery strategies 
to fail [120, 121]. CRC therapy will only be successful if 
strategies involve either the differentiation or elimination of 
suppressive cells. This strategy will be more effective than 
direct cancer therapy that attempts to eliminate tumor cells. 
Consideration of immune suppressive parameters will pro-
vide better stratification of CRC patient treatment.
Currently there are about 46 active (recruiting) immu-
notherapy trials against CRC (Clin Trials. Gov accessed 
on July 23, 2017). Peptide vaccines targeting HER-2/Neu, 
P-53, SART-3, and CEA in CRC have been studied. These 
vaccines are generally well tolerated but are far from a suc-
cessful treatment. Most of the current CRC immunothera-
pies can be grouped as checkpoint blockade inhibitors like 
anti-CTLA4 [122], PDL-L1 [123], PD-1 [124], LAG-3; 
approved FDA targeted antibodies like bevacizumab, cetuxi-
mab, ramucirumab, and panitumumab; ACT (adoptive T cell 
therapy) and virus-mediated therapies. These therapies are 
tried either as adjuvants or as combinations. Current CRC 
immunotherapy targets the highly expressed tumor antigens 
like CEA, APC, MAGE, MUC-1, and survivin [125], or 
common mutations in the WNT, MAPK, TGF, P53, or apop-
tosis pathway [126–128]. A recent paper targeting mutant 
KRAS in CRC patients using ACT observed objective pro-
gressive regression [129]. ACT targeting various known 
CRC mutations in combination with checkpoint inhibitors 
and modulating the persistent immune suppressive factors 
would lead to effective therapies. Data from a phase 2 trial of 
pembrolizumab for the treatment of tumors with and without 
mismatch repair deficiency support the hypothesis that mis-
match repair-deficient tumors are more responsive to PD-1 
blockade than are mismatch repair-proficient tumors [130].
Emerging Approaches to Personalizing 
Cancer Treatment
Genomic Testing
Personalizing cancer treatment that is tailored to an indi-
vidual’s genomic profile is a cornerstone of precision 
oncology [131]. NGS of DNA from tumor tissue can iden-
tify gene variants that could be targets of specific cancer 
therapies. These variants can be inherited (germline) or 
acquired (somatic) [132]. For example, poly(ADP-ribose) 
polymerase (PARP) inhibitors are effective in killing cancer 
cells that are deficient in repair of double-stranded DNA 
breaks. This is due to a pathogenic variant in the BRCA1 or 
BRCA2 gene [133] and other germline variants, which cause 
hereditary breast-ovarian cancer syndrome [134]. Tumors 
deficient in DNA mismatch repair (MMR) due to a patho-
genic variant in the MSH2, MLH1, MSH6, PMS2, or EPCAM 
genes are responsive to antibodies or ligands that block the 
programmed death 1 (PD1) pathway [130]. These germline 
variants cause Lynch syndrome, the most common cause of 
hereditary CRC [135].
The VHA has undertaken feasibility studies on the use 
of NGS testing of tumor samples [136]. Tumors tested with 
multi-gene NGS sequencing through 1 of 2 contracted ven-
dors were identified from POP records, and cancer char-
acteristics were extracted from POP and medical records. 
Drug use data were obtained from the VA Corporate Data 
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Warehouse. NGS testing results and annotations were 
extracted from POP records. Of a total of 1292 tumor sam-
ples sent for NGS testing since program inception in 2015, 
the most common diagnoses have been lung (561: adeno 
418, squamous 143), gastrointestinal [109], lymph node 
[75], liver [56], head and neck [52], and prostate [43]. The 
rate of sample test requests increased rapidly after national 
dissemination in July 2016 (from a mean of 23 samples/
month prior to launch to a mean of 126 samples/month 
3 months later), as did the number of participating facilities 
(from a mean of 8/month to a mean of 27/month). Sequenc-
ing success rate increased from 68 to 71% over the same 
interval, while mean turnaround time remained similar at 
19.7 and 19.1 days, respectively. NGS was requested for 61 
patients with CRC, with almost all requested after dissemi-
nation of POP across the USA. Only one case failed to gen-
erate NGS results (98% success rate). Twenty-two patients 
had mutations targetable with an off-label FDA-approved 
drug, but no patient received NGS-directed treatment. These 
results suggest that tumor NGS testing as part of POP in the 
VA healthcare system is feasible with a high rate of test-
ing success in CRC, but effective implementation strategies 
are needed to ensure uptake of treatments targeting tumor 
sequencing results.
The Spheroid and Organoid Culture Approaches 
to Assess Clinical Drug Response
Animal models of human CRC do not recapitulate human 
disease and frequently yield overly optimistic results [137, 
138]. In the absence of accurate murine models, robust cel-
lular models of CRC are considered critical. With over 150 
CRC cell lines having been investigated, there is an abun-
dance of cell line resources to investigate [139]. A number 
of different colon two-dimensional (2D) cell techniques, 
also referred to as “flat” cell cultures, have been described 
including the flow cell used for organ-on-chip models [140]. 
Despite progress made, these flat cultures are significantly 
different from in vivo tumor cells biochemically, physiologi-
cally, and genetically. Another approach that has been devel-
oped is in vitro multi-cell tumor-like cultures referred to 
as spheroids, tumoroids, or organoid culture systems [141]. 
Whether they are scaffold-free or scaffold-based 3D plat-
forms, they fail to fully recapitulate in vivo tumors [141]. 
More importantly, they are cumbersome, costly, and not 
adaptable to perfusion-driven culture. Though very few of 
these have progressed to clinical testing realm the spheroid 
technologies are under intense investigation for their use in 
clinical drug response analyses.
Notably, several studies reported success in predicting 
CRC clinical drug response using organoid culture, also 
referred to as histoculture technique. Thus, an evaluation of 
86 chemotherapy regimens using the 3D histoculture drug 
response assay (HDRA) for CRCs showed that the corre-
lation of HDRA to the clinical response to chemotherapy 
was 66% (sensitivity 73%, specificity 55%) [142]. In another 
study, ATP-CRA-guided chemotherapy group showed bet-
ter treatment response (48.4 vs. 21.9%, p = 0.027) and a 
higher rate of resection of hepatic lesions (35.5 vs. 12.5%, 
p = 0 [143]. Also, the extreme drug response assay (EDRA), 
developed as an exclusion test to identify drugs unlikely to 
elicit a response [144], was used to analyze the therapeutic 
efficacy of treatment for CRC patients. Thus, in the clinical 
correlation of 25 Duke’s D patients with EDRA, the sensitiv-
ity and specificity of the assay were 100 and 95%, respec-
tively, suggesting that EDRA obtained at initial diagnosis 
may be useful for the selection of therapeutic regimens for 
metastatic disease [145, 146]. While these studies indicate 
the value of ex vivo organoid cultures, these results need to 
be replicated in multicenter clinical trials.
Tumoroid Technology for Clinical Drug Response
A fiber-inspired smart scaffold (FiSS) tumoroid culture plat-
form has been developed that allows the formation of tumor-
like organoids with molecular signatures of tumors. These 
cancer cells obtained from ex vivo tumor biopsies mimic 
patient tumors [141, 147, 148] (Fig. 5). The novelty of this 
platform lies in its simplicity, reproducibility, and similarity 
to in vivo tumors in terms of its drug responsiveness. Recent 
pilot proof-of-concept studies showed that cells of tumors 
from cancer patients, when cultured on a tumoroid platform, 
formed tumoroids that exhibited differential drug response 
[141, 147, 148]. Tumoroids were also found to expand can-
cer stem cells (CSCs) up to 30-fold, with cancer cells origi-
nating from several cancer cell lines including cells from 
breast, lung, and colon tumor xenografts.
In the post-genomic era the development of microarray 
technology has allowed use of genomic data to help define 
which patients would benefit most from a specific therapy 
[149]. For example, gene signatures have been developed 
and validated against large retrospective databases to risk 
stratify patients to selectively receive adjuvant treatments 
for breast cancer [150]. However, genomic/genetic tests 
are based on pathway analysis of several genes with muta-
tions out of more than 1000 genes that play a role in cancer 
pathogenesis. They may reveal potential adverse responses 
to drugs. However, the results do not indicate one or two 
potential drugs for effective treatments but rather suggest 
excluding therapies that may cause adverse effects.
One novel approach to PCT involves use of the patient-
derived perfused tumoroid (PPT) platform, which mimics 
patient’s tumor. PPT provides a simple, rapid, scalable, and 
inexpensive in vitro tumor model that better replicates the 
structure, physiology, and function of tissues. It also recre-
ates the in vivo morphology and arrangement of individual 
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cells and the concentration gradients of both signaling 
molecules and therapeutic agents [151]. This platform can 
be used to culture tumoroids utilizing human tumor cells 
(Fig. 5) with or without stromal cells. These are derived 
from biopsy or surgery discard tumor samples from patients. 
The PPT also promotes tumoroids in a manner that can be 
adapted for cell viability measurements (e.g., Celltiter-Glo 
or PrestoBlue). Preliminary data suggest that PCT tests 
will fully recapitulate in vivo tumors and will provide evi-
dence for the best drug to treat each patient’s tumor. Further, 
expanding PCT to include first genetic/genomic testing that 
predicts potential therapies, followed by tumoroid-based 
clinical drug response assay, is expected to significantly 
improve the standard of personalized therapy. Adding 
evidence-based, simple-to-analyze, and ready-to-prescribe 
therapies will significantly improve personalized cancer 
treatment. Thus, a cell-genomic approach that combines 
NGS-based genomic testing with a PPT-based clinical drug 
response assay is expected to provide an exciting approach 
for PCT and may aid in discovery of novel anticancer agents.
Cancer Stem Cell Biology and Drug Discovery
Pivotal to successful CRC treatments are CSCs, referred to 
as the “seeds” of tumors, which play a central role in pro-
cesses such as tumor initiation, drug resistance, invasion, 
and metastasis. While chemo-, radio- and immune-thera-
pies are more effective at killing bulk tumor cells, the qui-
escent CSCs manage to escape and seed new tumor growth. 
CSC phenotype in human colon cancer is associated with 
poor prognosis [152, 153]. Hence, a therapeutic approach 
has been to target CSCs through either inhibition of self-
renewal or induction of differentiation [154, 155]. A major 
barrier to CSC research, however, is the small proportion 
of these cells in tumors. With the possibility to expand 
CSCs by tumoroid cultures has opened new avenues for 
anti-CSC drug discovery. An NCI library of FDA-approved 
drugs was screened using FiSS tumoroid platform, which 
revealed that mithramycin A, idarubicin, and daunorubicin 
were the most potent inhibitors of HT-29 cell viability; and 
cisplatin, 6-thioguanine, and cytarabine were the least potent 
inhibitors. Further studies have revealed that mithramycin A 
treatment can reduce CSC self-renewal as well as expression 
of stemness genes. These results suggest that mithramycin A 
may be used as a single agent or in combination with other 
chemo- or immuno-therapy to most effectively treat or pos-
sibly ‘cure’ CRCs.
In addition to these efforts, two major pathways have been 
exploited to screen for anti-CSC drugs. First, application of 
HTS on a library of small molecules targeting EMT in breast 
cancer cells led to identification of four candidates: salino-
mycin, a polyketide synthase-derived natural product, and 
probes ML239, ML243, and ML245, which are chemically 
synthesizable, small hydrophobic molecules [156–160]. A 
second target signaling pathway for CSCs involves interac-
tion of glycosaminoglycans (GAGs) with factors involved in 
growth and/or differentiation signaling that regulate CSCs, 
including growth factors (e.g., fibroblast growth factors, 
TGF-β, bone morphogenetic proteins), cytokines (e.g., inter-
leukins-6 and -8), or morphogens (e.g., Hedgehog, Notch). 
Fig. 5  Schematics of tumoroid technology platform for anti-CSC drug discovery and tumoroid-based clinical drug response assay
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These in turn influence many transcription factors including 
Nanog, Oct4, and SOX2 and c-MYC, which play critical 
roles in deciding the fate of CSCs [161–163]. In sum, the 
identification of only four CSC targeting molecules so far 
using CSC-pathway screening approach for breast CSCs 
highlights the difficulty of targeting CSCs. For the anti-CSC 
paradigm to translate into therapeutic success, a more fun-
damental and generalizable approach is needed.
Concluding Remarks and Opportunities
Our review has identified key research directions in the 
field of CRC, as summarized below. a) Current genomic 
testing includes primarily somatic mutations only, and not 
genetic testing for germline mutations. Adding the latter 
might allow for more accurate CRC risk assessment, sur-
veillance and prevention. Also, marker(s) such as specific 
mucins could serve as a powerful adjunct to colonoscopy by 
enabling efficient detection of SSA/Ps. b) Several emerging 
genetic biomarkers as well as cell-free miRNAs and small 
non-coding RNAs have been suggested as noninvasive and 
highly sensitive candidate markers for CRCs. They will 
require large clinical trial-based validation. c) In relation 
to precision treatment approaches, developments in ex vivo 
cell-genomics technologies and the potential to combine 
genomic/genetic testing with tumoroid-based drug response 
testing might provide more accurate clinical efficacy of cer-
tain drugs in individual patients. d) Integrating targeted 
tumor imaging preoperatively and delineating tumor mar-
gins intraoperatively with fluorescent labeling can improve 
the precision of surgical resection. e) Given the pivotal role 
of cancer-initiating stem cells in CRC progression, the stem 
cell niches discovered thus far, such as CEACAM/TGF-β 
and M3R, need further investigation. Other stem cell niches, 
such as telomerase, CTCF, CEA, E-cadherin, and β-catenin, 
may be equally important in developing targeted, preventive 
therapies against CRC. f) CRC tumoroid/organoid technol-
ogy using polymeric nanofiber scaffolds to expand CSCs 
ex vivo is of considerable interest. Specifically, tumoroid 
technology can be used to expand CSCs of hard-to-detect 
SSA/P neoplasms, which can be characterized and inves-
tigated for CRC stem cell niches and used for evaluating 
existing chemo- and immunotherapies.
Acknowledgments This VA Colorectal Cancer Cell-genomics Con-
sortium (VA4C) meeting was supported by a Department of Veterans 
Affairs Biomedical Laboratory Research and Development Service 
field-based meeting award to Dr. Shyam Mohapatra and Dr. Subhra 
Mohapatra. The contents of any report, written material or manuscripts 
emanating from this meeting do not represent the views of the Depart-
ment of Veterans Affairs or the United States Government. The VA4C 
would like to acknowledge the support of Ms. Christen Bouchard in 
preparation of this manuscript.
Compliance with ethical standards 
Conflict of interest All authors except the following have indicated no 
financial conflicts of interests in relation to writing of this review. Even 
though not relevant to this review, Dr. Hemant K Roy has declared that 
he is a co-founder and shareholder in startup company Nanocytomics 
and American BioOptics LLC. Additionally, Subhra Mohapatra (co-
founder and scientific advisor), Shyam Mohapatra (co-founder and sci-
entific advisor) and the University of South Florida have equity interest 
in Transgenex Nanobiotech Inc. The terms of the conflict management 
have been reviewed and approved by the University of South Florida, 
Tampa, in accordance with its conflict of interest policies.
Open Access This article is distributed under the terms of the Crea-
tive Commons Attribution-NonCommercial 4.0 International License 
(http://creativecommons.org/licenses/by-nc/4.0/), which permits any 
noncommercial use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the 
source, provide a link to the Creative Commons license, and indicate 
if changes were made.
References
 1. Zauber AG, Winawer SJ, O’Brien MJ, et al. Colonoscopic pol-
ypectomy and long-term prevention of colorectal-cancer deaths. 
N Engl J Med. 2012;366:687–696.
 2. Pan J, Xin L, Ma YF, et al. Colonoscopy reduces colorectal can-
cer incidence and mortality in patients with non-malignant find-
ings: a meta-analysis. Am J Gastroenterol. 2016;111:355–365.
 3. Nelson KM, Starkebaum GA, Reiber GE. Veterans using and 
uninsured veterans not using Veterans Affairs (VA) health care. 
Public Health Rep. 2007;122:93–100.
 4. Zullig LL, Williams CD, Fortune-Britt AG. Lung and colorectal 
cancer treatment and outcomes in the Veterans Affairs health care 
system. Cancer Manag Res. 2015;7:19–35.
 5. Fakih MG. Metastatic colorectal cancer: current state and future 
directions. J Clin Oncol. 2015;33:1809–1824.
 6. Fearon ER, Vogelstein B. A genetic model for colorectal tumo-
rigenesis. Cell. 1990;61:759–767.
 7. Qiu M, Hu J, Yang D, et  al. Pattern of distant metasta-
ses in colorectal cancer: a SEER based study. Oncotarget. 
2015;6:38658–38666.
 8. Enquist IB, Good Z, Jubb AM, et al. Lymph node-independent 
liver metastasis in a model of metastatic colorectal cancer. Nat 
Commun. 2014;5:3530.
 9. Lambert AW, Pattabiraman DR, Weinberg RA. Emerging bio-
logical principles of metastasis. Cell. 2017;168:670–691.
 10. Carethers JM, Jung BH. Genetics and genetic biomark-
ers in sporadic colorectal cancer. Gastroenterology. 
2015;149:1177e3–1190e3.
 11. Okugawa Y, Grady WM, Goel A. Epigenetic alterations in 
colorectal cancer: emerging biomarkers. Gastroenterology. 
2015;149:1204–1225.e12.
 12. Pancione M, Remo A, Colantuoni V. Genetic and epigenetic 
events generate multiple pathways in colorectal cancer progres-
sion. Patholog Res Int. 2012;2012:509348.
 13. Buda A, De Bona M, Dotti I, et al. Prevalence of different 
subtypes of serrated polyps and risk of synchronous advanced 
colorectal neoplasia in average-risk population undergoing 
first-time colonoscopy. Clin Transl Gastroenterol. 2012;3:e6.
 14. Crockett SD, Snover DC, Ahnen DJ, et al. Sessile serrated 
adenomas: an evidence-based guide to management. Clin Gas-
troenterol Hepatol. 2015;13:11–26.e1.
1134 Digestive Diseases and Sciences (2018) 63:1123–1138
1 3
 15. IJSPEERT JE, Rana SA, Atkinson NS, et  al. Clinical 
risk factors of colorectal cancer in patients with serrated 
polyposis syndrome: a multicentre cohort analysis. Gut. 
2017;66:278–284.
 16. East JE, Atkin WS, Bateman AC, et al. British Society of Gas-
troenterology position statement on serrated polyps in the colon 
and rectum. Gut. 2017;66:1181–1196.
 17. Lieberman DA, Rex DK, Winawer SJ, et al. Guidelines for colo-
noscopy surveillance after screening and polypectomy: a con-
sensus update by the US Multi-Society Task Force on Colorectal 
Cancer. Gastroenterology. 2012;143:844–857.
 18. Freeman HJ. Heterogeneity of colorectal adenomas, the serrated 
adenoma, and implications for screening and surveillance. World 
J Gastroenterol. 2008;14:3461–3463.
 19. Grady WM, Carethers JM. Genomic and epigenetic insta-
bility in colorectal cancer pathogenesis. Gastroenterology. 
2008;135:1079–1099.
 20. Yang S, Farraye FA, Mack C, et al. BRAF and KRAS Mutations 
in hyperplastic polyps and serrated adenomas of the colorectum: 
relationship to histology and CpG island methylation status. Am 
J Surg Pathol. 2004;28:1452–1459.
 21. Huang CS, O’Brien MJ, Yang S, et al. Hyperplastic polyps, ser-
rated adenomas, and the serrated polyp neoplasia pathway. Am J 
Gastroenterol. 2004;99:2242–2255.
 22. Das V, Kalita J, Pal M. Predictive and prognostic biomarkers in 
colorectal cancer: a systematic review of recent advances and 
challenges. Biomed Pharmacother. 2017;87:8–19.
 23. Felton J, Raufman JP. Is the ColDx assay a valid prognos-
tic mrker for stage II colon cancer? Transl Cancer Res. 
2017;5:S1157–S1159.
 24. Singh MP, Rai S, Suyal S, et al. Genetic and epigenetic markers 
in colorectal cancer screening: recent advances. Expert Rev Mol 
Diagn. 2017;17:665–685.
 25. Barontini J, Antinucci M, Tofanelli S, et al. Association between 
polymorphisms of TAS2R16 and susceptibility to colorectal can-
cer. BMC Gastroenterol. 2017;17:104.
 26. Tanskanen T, van den Berg L, Valimaki N, et al. Genome-wide 
association study and meta-analysis in Northern European popu-
lations replicate multiple colorectal cancer risk loci. Int J Can-
cer. 2018;142:540–546.
 27. Hanley MP, Hahn MA, Li AX, et al. Genome-wide DNA meth-
ylation profiling reveals cancer-associated changes within early 
colonic neoplasia. Oncogene. 2017;36:5035–5044.
 28. Li Y, Cao H, Jiao Z, et al. Carcinoembryonic antigen interacts 
with TGF-{beta} receptor and inhibits TGF-{beta} signaling in 
colorectal cancers. Cancer Res. 2010;70:8159–8168.
 29. Grady WM, Markowitz SD. Genetic and epigenetic alterations in 
colon cancer. Annu Rev Genomics Hum Genet. 2002;3:101–128.
 30. Hoosein NM, McKnight MK, Levine AE, et al. Differential sen-
sitivity of subclasses of human colon carcinoma cell lines to the 
growth inhibitory effects of transforming growth factor-beta 1. 
Exp Cell Res. 1989;181:442–453.
 31. Yashiro M, Hirakawa K, Boland CR. Mutations in TGFbeta-
RII and BAX mediate tumor progression in the later stages of 
colorectal cancer with microsatellite instability. BMC Cancer. 
2010;10:303.
 32. Takagi Y, Kohmura H, Futamura M, et al. Somatic alterations of 
the DPC4 gene in human colorectal cancers in vivo. Gastroen-
terology. 1996;111:1369–1372.
 33. Takagi Y, Koumura H, Futamura M, et al. Somatic alterations 
of the SMAD-2 gene in human colorectal cancers. Br J Cancer. 
1998;78:1152–1155.
 34. Massague J, Blain SW, Lo RS. TGFbeta signaling in growth 
control, cancer, and heritable disorders. Cell. 2000;103:295–309.
 35. Takaku K, Oshima M, Miyoshi H, et al. Intestinal tumorigenesis 
in compound mutant mice of both Dpc4 (Smad4) and Apc genes. 
Cell. 1998;92:645–656.
 36. Tiernan JP, Perry SL, Verghese ET, et al. Carcinoembryonic 
antigen is the preferred biomarker for in vivo colorectal cancer 
targeting. Br J Cancer. 2013;108:662–667.
 37. Cancer Genome Atlas N. Comprehensive molecular char-
acterization of human colon and rectal cancer. Nature. 
2012;487:330–337.
 38. Chakrabarty S, Tobon A, Varani J, et al. Induction of carcinoem-
bryonic antigen secretion and modulation of protein secretion/
expression and fibronectin/laminin expression in human colon 
carcinoma cells by transforming growth factor-beta. Cancer Res. 
1988;48:4059–4064.
 39. Michalopoulos G, Tzathas C. Serrated polyps of right colon: 
guilty or innocent? Ann Gastroenterol. 2013;26:212–219.
 40. Sandmeier D, Seelentag W, Bouzourene H. Serrated polyps 
of the colorectum: is sessile serrated adenoma distinguishable 
from hyperplastic polyp in a daily practice? Virchows Arch. 
2007;450:613–618.
 41. Yang HM, Mitchell JM, Sepulveda JL, et al. Molecular and his-
tologic considerations in the assessment of serrated polyps. Arch 
Pathol Lab Med. 2015;139:730–741.
 42. Schreiner MA, Weiss DG, Lieberman DA. Proximal and large 
hyperplastic and nondysplastic serrated polyps detected by 
colonoscopy are associated with neoplasia. Gastroenterology. 
2010;139:1497–1502.
 43. Rex DK, Ahnen DJ, Baron JA, et al. Serrated lesions of the colo-
rectum: review and recommendations from an expert panel. Am 
J Gastroenterol. 2012;107:1315–1329. (quiz 1314, 1330).
 44. O’Brien MJ. Hyperplastic and serrated polyps of the colorectum. 
Gastroenterol Clin North Am. 2007;36:947–968. (viii).
 45. IJspeert JE, Vermeulen L, Meijer GA, et al. Serrated neoplasia-
role in colorectal carcinogenesis and clinical implications. Nat 
Rev Gastroenterol Hepatol. 2015;12:401–409.
 46. Hetzel JT, Huang CS, Coukos JA, et al. Variation in the detection 
of serrated polyps in an average risk colorectal cancer screening 
cohort. Am J Gastroenterol. 2010;105:2656–2664.
 47. Khaidakov M, Lai KK, Roudachevski D, et al. Gastric pro-
teins MUC5AC and TFF1 as potential diagnostic markers of 
colonic sessile serrated adenomas/polyps. Am J Clin Pathol. 
2016;146:530–537.
 48. Gonzalo DH, Lai KK, Shadrach B, et al. Gene expression profil-
ing of serrated polyps identifies annexin A10 as a marker of a 
sessile serrated adenoma/polyp. J Pathol. 2013;230:420–429.
 49. Krishn SR, Kaur S, Sheinin YM, et al. Mucins and associated 
O-glycans based immunoprofile for stratification of colorectal 
polyps: clinical implication for improved colon surveillance. 
Oncotarget. 2017;8:7025–7038.
 50. Fodde R, Brabletz T. Wnt/beta-catenin signaling in can-
cer stemness and malignant behavior. Curr Opin Cell Biol. 
2007;19:150–158.
 51. Cheng K, Shang AC, Drachenberg CB, et al. Differential expres-
sion of M3 muscarinic receptors in progressive colon neoplasia 
and metastasis. Oncotarget. 2017;8:21106–21114.
 52. Said AH, Hu S, Abutaleb A, et al. Interacting post-muscarinic 
receptor signaling pathways potentiate matrix metalloprotein-
ase-1 expression and invasion of human colon cancer cells. Bio-
chem J. 2017;474:647–665.
 53. Raufman JP, Cheng K, Saxena N, et al. Muscarinic receptor ago-
nists stimulate matrix metalloproteinase 1-dependent invasion 
of human colon cancer cells. Biochem Biophys Res Commun. 
2011;415:319–324.
 54. Kessenbrock K, Plaks V, Werb Z. Matrix metalloproteinases: reg-
ulators of the tumor microenvironment. Cell. 2010;141:52–67.
1135Digestive Diseases and Sciences (2018) 63:1123–1138 
1 3
 55. Lew EA, Lewin KJ, Zarchy T, et al. Adenocarcinoma of the colon 
with neuroendocrine features and secretory diarrhea. Am J Gas-
troenterol. 1999;94:1692–1694.
 56. Le SV, Yamaguchi DJ, McArdle CA, et al. PAC1 and PACAP 
expression, signaling, and effect on the growth of HCT8, human 
colonic tumor cells. Regul Pept. 2002;109:115–125.
 57. Germano PM, Le SV, Oh DS, et al. Differential coupling of the 
PAC1 SV1 splice variant on human colonic tumors to the activa-
tion of intracellular cAMP but not intracellular Ca2 + does not 
activate tumor proliferation. J Mol Neurosci. 2004;22:83–92.
 58. Ze EY, Kim BJ, Jun DH, et al. The fatty liver index: a simple 
and accurate predictor of colorectal adenoma in an average-risk 
population. Dis Colon Rectum. 2018;61:36–42.
 59. Rustagi T, Zarookian EI, Qasba O, et al. Chronic hepatitis C 
as a risk factor for colorectal adenoma. Int J Colorectal Dis. 
2014;29:75–80.
 60. Yi SW, Ohrr H, Hong JS, et al. Agent orange exposure and preva-
lence of self-reported diseases in korean vietnam veterans. J Prev 
Med Public Health. 2013;46:213–225.
 61. Shaw E, Warkentin MT, McGregor SE, et al. Intake of dietary 
fibre and lifetime non-steroidal anti-inflammatory drug (NSAID) 
use and the incidence of colorectal polyps in a population 
screened for colorectal cancer. J Epidemiol Community Health. 
2017;71:961–969.
 62. Wang L, Jacobs JP, Lagishetty V, et al. High-protein diet pro-
motes sensitivity to cholecystokinin and shifts the cecal microbi-
ome without altering brain inflammation in diet-induced obesity 
in rats. Am J Physiol Regul Integr Comput Physiol. 2017. https ://
doi.org/10.1152/ajpre gu001 05201 7.
 63. Wang LJJ, Lagishetty V, Yuan PQ, et al. Am J Physiol Regul 
Integr Comput Physiol. 2017;313:R473–R486.
 64. Li R, Yang J, Saffari A, et al. Ambient ultrafine particle ingestion 
alters gut microbiota in association with increased atherogenic 
lipid metabolites. Sci Rep. 2017;7:42906.
 65. O’Brien MJ, Gibbons D. The adenoma-carcinoma sequence in 
colorectal neoplasia. Surg Oncol Clin N Am. 1996;5:513–530.
 66. Lakoff J, Paszat LF, Saskin R, et al. Risk of developing proxi-
mal versus distal colorectal cancer after a negative colonos-
copy: a population-based study. Clin Gastroenterol Hepatol. 
2008;6:1117–1121. (quiz 1064).
 67. Kaminski MF, Regula J, Kraszewska E, et al. Quality indicators 
for colonoscopy and the risk of interval cancer. N Engl J Med. 
2010;362:1795–1803.
 68. Pickhardt PJ, Nugent PA, Mysliwiec PA, et  al. Location of 
adenomas missed by optical colonoscopy. Ann Intern Med. 
2004;141:352–359.
 69. Rex DK. Maximizing detection of adenomas and cancers during 
colonoscopy. Am J Gastroenterol. 2006;101:2866–2877.
 70. Matsumoto T, Iida M, Kuwano Y, et al. Small nonpolypoid neo-
plastic lesions of the colon: endoscopic features with emphasis 
on their progression. Gastrointest Endosc. 1995;41:135–140.
 71. Brooker JC, Saunders BP, Shah SG, et al. Total colonic dye-spray 
increases the detection of diminutive adenomas during routine 
colonoscopy: a randomized controlled trial. Gastrointest Endosc. 
2002;56:333–338.
 72. Anderson JC, Butterly LF. Colonoscopy: quality indicators. Clin 
Transl Gastroenterol. 2015;6:e77.
 73. Rex DK, Kahi C, O’Brien M, et al. The American Society for 
Gastrointestinal Endoscopy PIVI (Preservation and incorpora-
tion of valuable endoscopic innovations) on real-time endoscopic 
assessment of the histology of diminutive colorectal polyps. Gas-
trointest Endosc. 2011;73:419–422.
 74. Hassan C, Pickhardt PJ, Rex DK. A resect and discard strategy 
would improve cost-effectiveness of colorectal cancer screening. 
Clin Gastroenterol Hepatol. 2010;8:865–869.
 75. Ignjatovic A, East JE, Suzuki N, et al. Optical diagnosis of 
small colorectal polyps at routine colonoscopy (Detect InSpect 
ChAracterise Resect and Discard; DISCARD trial): a prospec-
tive cohort study. Lancet Oncol. 2009;10:1171–1178.
 76. Subramanian V, Mannath J, Hawkey CJ, et al. High definition 
colonoscopy vs. standard video endoscopy for the detection of 
colonic polyps: a meta-analysis. Endoscopy. 2011;43:499–505.
 77. Kahi CJ, Anderson JC, Waxman I, et al. High-definition chro-
mocolonoscopy vs. high-definition white light colonoscopy for 
average-risk colorectal cancer screening. Am J Gastroenterol. 
2010;105:1301–1307.
 78. Leufkens AM, DeMarco DC, Rastogi A, et  al. Effect of a 
retrograde-viewing device on adenoma detection rate dur-
ing colonoscopy: the TERRACE study. Gastrointest Endosc. 
2011;73:480–489.
 79. Gralnek IM, Siersema PD, Halpern Z, et al. Standard forward-
viewing colonoscopy versus full-spectrum endoscopy: an inter-
national, multicentre, randomised, tandem colonoscopy trial. 
Lancet Oncol. 2014;15:353–360.
 80. Floer M, Biecker E, Fitzlaff R, et al. Higher adenoma detec-
tion rates with endocuff-assisted colonoscopy—a randomized 
controlled multicenter trial. PLoS ONE. 2014;9:e114267.
 81. Dik VK, Gralnek IM, Segol O, et al. Multicenter, randomized, 
tandem evaluation of EndoRings colonoscopy–results of the 
CLEVER study. Endoscopy. 2015;47:1151–1158.
 82. Hohenberger W, Weber K, Matzel K, et al. Standardized sur-
gery for colonic cancer: complete mesocolic excision and 
central ligation–technical notes and outcome. Colorectal Dis. 
2009;11:354–364. (discussion 364-5).
 83. Andreoni B, Chiappa A, Bertani E, et al. Surgical outcomes for 
colon and rectal cancer over a decade: results from a consecu-
tive monocentric experience in 902 unselected patients. World 
J Surg Oncol. 2007;5:73.
 84. Campos FG, Calijuri-Hamra MC, Imperiale AR, et al. Locally 
advanced colorectal cancer: results of surgical treatment and 
prognostic factors. Arq Gastroenterol. 2011;48:270–275.
 85. Mayo SC, Pulitano C, Marques H, et al. Surgical management 
of patients with synchronous colorectal liver metastasis: a mul-
ticenter international analysis. J Am Coll Surg. 2013;216:707–
716. (discussion 716-8).
 86. Ruo L, Guillem JG. Surgical management of primary colorectal 
cancer. Surg Oncol. 1998;7:153–163.
 87. Yedibela S, Klein P, Feuchter K, et al. Surgical management of 
pulmonary metastases from colorectal cancer in 153 patients. 
Ann Surg Oncol. 2006;13:1538–1544.
 88. Manfredi S, Benhamiche AM, Meny B, et  al. Population-
based study of factors influencing occurrence and prognosis 
of local recurrence after surgery for rectal cancer. Br J Surg. 
2001;88:1221–1227.
 89. Manfredi S, Bouvier AM, Lepage C, et al. Incidence and pat-
terns of recurrence after resection for cure of colonic cancer 
in a well defined population. Br J Surg. 2006;93:1115–1122.
 90. Abulafi AM, Williams NS. Local recurrence of colorectal 
cancer: the problem, mechanisms, management and adjuvant 
therapy. Br J Surg. 1994;81:7–19.
 91. Bouvet M, Hoffman RM. Glowing tumors make for better 
detection and resection. Sci Transl Med. 2011;3:110fs10.
 92. Metildi CA, Kaushal S, Luiken GA, et  al. Fluorescently 
labeled chimeric anti-CEA antibody improves detection and 
resection of human colon cancer in a patient-derived ortho-
topic xenograft (PDOX) nude mouse model. J Surg Oncol. 
2014;109:451–458.
 93. Nguyen QT, Tsien RY. Fluorescence-guided surgery with live 
molecular navigation–a new cutting edge. Nat Rev Cancer. 
2013;13:653–662.
1136 Digestive Diseases and Sciences (2018) 63:1123–1138
1 3
 94. Vahrmeijer AL, Hutteman M, van der Vorst JR, et al. Image-
guided cancer surgery using near-infrared fluorescence. Nat 
Rev Clin Oncol. 2013;10:507–518.
 95. DeLong JC, Hoffman RM, Bouvet M. Current status and future 
perspectives of fluorescence-guided surgery for cancer. Expert 
Rev Anticancer Ther. 2016;16:71–81.
 96. Hiroshima Y, Lwin TM, Murakami T, et al. Effective fluores-
cence-guided surgery of liver metastasis using a fluorescent 
anti-CEA antibody. J Surg Oncol. 2016;114:951–958.
 97. Hiroshima Y, Maawy A, Metildi CA, et al. Successful fluores-
cence-guided surgery on human colon cancer patient-derived 
orthotopic xenograft mouse models using a fluorophore-con-
jugated anti-CEA antibody and a portable imaging system. J 
Laparoendosc Adv Surg Tech A. 2014;24:241–247.
 98. Kaushal S, McElroy MK, Luiken GA, et  al. Fluorophore-
conjugated anti-CEA antibody for the intraoperative imag-
ing of pancreatic and colorectal cancer. J Gastrointest Surg. 
2008;12:1938–1950.
 99. Metildi CA, Kaushal S, Pu M, et al. Fluorescence-guided sur-
gery with a fluorophore-conjugated antibody to carcinoem-
bryonic antigen (CEA), that highlights the tumor, improves 
surgical resection and increases survival in orthotopic 
mouse models of human pancreatic cancer. Ann Surg Oncol. 
2014;21:1405–1411.
 100. Metildi CA, Kaushal S, Snyder CS, et al. Fluorescence-guided 
surgery of human colon cancer increases complete resection 
resulting in cures in an orthotopic nude mouse model. J Surg 
Res. 2013;179:87–93.
 101. Hiroshima Y, Lwin TM, Murakami T, et al. Effective fluores-
cence-guided surgery of liver metastasis using a fluorescent anti-
CEA antibody. J Surg Oncol. 2016;114:951–958.
 102. Yazaki PJ, Sherman MA, Shively JE, et al. Humanization of the 
anti-CEA T84.66 antibody based on crystal structure data. Pro-
tein Eng Des Sel. 2004;17:481–489.
 103. Gutowski M, Framery B, Boonstra MC, et al. SGM-101: An 
innovative near-infrared dye-antibody conjugate that targets CEA 
for fluorescence-guided surgery. Surg Oncol. 2017;26:153–162.
 104. Park JY, Murakami T, Lee JY, et al. Fluorescent-antibody target-
ing of insulin-like growth factor-1 receptor visualizes metastatic 
human colon cancer in orthotopic mouse models. PLoS ONE. 
2016;11:e0146504.
 105. Yano S, Takehara K, Miwa S, et al. Improved resection and 
outcome of colon-cancer liver metastasis with fluorescence-
guided surgery using in situ GFP labeling with a telomerase-
dependent adenovirus in an orthotopic mouse model. PLoS ONE. 
2016;11:e0148760.
 106. Metildi CA, Felsen CN, Savariar EN, et al. Ratiometric acti-
vatable cell-penetrating peptides label pancreatic cancer, ena-
bling fluorescence-guided surgery, which reduces metastases 
and recurrence in orthotopic mouse models. Ann Surg Oncol. 
2015;22:2082–2087.
 107. Jafari MD, Wexner SD, Martz JE, et al. Perfusion assessment in 
laparoscopic left-sided/anterior resection (PILLAR II): a multi-
institutional study. J Am Coll Surg. 2015;220(82–92):e1.
 108. Tipirneni KE, Warram JM, Moore LS, et al. Oncologic pro-
cedures amenable to fluorescence-guided surgery. Ann Surg. 
2017;266:36–47.
 109. Inoue Y, Kusunoki M. Advances and directions in chemotherapy 
using implantable port systems for colorectal cancer: a historical 
review. Surg Today. 2014;44:1406–1414.
 110. Ahmed S, Johnson K, Ahmed O, et al. Advances in the man-
agement of colorectal cancer: from biology to treatment. Int J 
Colorectal Dis. 2014;29:1031–1042.
 111. Ciombor KK, Wu C, Goldberg RM. Recent therapeutic 
advances in the treatment of colorectal cancer. Annu Rev Med. 
2015;66:83–95.
 112. Xiong M, Lei Q, You X, et  al. Mannosylated liposomes 
improve therapeutic effects of paclitaxel in colon cancer mod-
els. J Microencapsul. 2017;34:513–521.
 113. Patras L, Sylvester B, Luput L, et al. Liposomal prednisolone 
phosphate potentiates the antitumor activity of liposomal 
5-fluorouracil in C26 murine colon carcinoma in vivo. Cancer 
Biol Ther. 2017;18:616–626.
 114. Slattery ML, Herrick JS, Stevens JR, et al. An assessment of 
database-validated microRNA target genes in normal colonic 
mucosa: implications for pathway analysis. Cancer Inform. 
2017;16:1176935117716405.
 115. Yao J, Zhang P, Li J, et al. MicroRNA-215 acts as a tumor 
suppressor in breast cancer by targeting AKT serine/threonine 
kinase 1. Oncol Lett. 2017;14:1097–1104.
 116. Zheng J, He S, Qi J, et al. Targeted CDX2 expression inhib-
its aggressive phenotypes of colon cancer cells in vitro and 
in vivo. Int J Oncol. 2017;51:478–488.
 117. Villalba M, Evans SR, Vidal-Vanaclocha F, et al. Role of TGF-
beta in metastatic colon cancer: it is finally time for targeted 
therapy. Cell Tissue Res. 2017;370:29–39.
 118. Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor 
cells as regulators of the immune system. Nat Rev Immunol. 
2009;9:162–174.
 119. Nagaraj S, Gabrilovich DI. Myeloid-derived suppressor cells. 
Adv Exp Med Biol. 2007;601:213–223.
 120. Nagaraj S, Gabrilovich DI. Myeloid-derived suppressor cells 
in human cancer. Cancer J. 2010;16:348–353.
 121. Nagaraj S, Gupta K, Pisarev V, et al. Altered recognition of 
antigen is a novel mechanism of CD8 + T cell tolerance in can-
cer. Nat Med. 2007;13:828–835.
 122. Chung KY, Gore I, Fong L, et al. Phase II study of the anti-
cytotoxic T-lymphocyte-associated antigen 4 monoclonal 
antibody, tremelimumab, in patients with refractory metastatic 
colorectal cancer. J Clin Oncol. 2010;28:3485–3490.
 123. Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of 
anti-PD-L1 antibody in patients with advanced cancer. N Engl 
J Med. 2012;366:2455–2465.
 124. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and 
immune correlates of anti-PD-1 antibody in cancer. N Engl J 
Med. 2012;366:2443–2454.
 125. Nagaraj S, Pisarev V, Kinarsky L, et al. Dendritic cell-based 
full-length survivin vaccine in treatment of experimental 
tumors. J Immunother. 2007;30:169–179.
 126. Koido S, Ohkusa T, Homma S, et al. Immunotherapy for colo-
rectal cancer. World J Gastroenterol. 2013;19:8531–8542.
 127. Xiang B, Snook AE, Magee MS, et al. Colorectal cancer immu-
notherapy. Discov Med. 2013;15:301–308.
 128. Signorini L, Delbue S, Ferrante P, et al. Review on the immu-
notherapy strategies against metastatic colorectal carcinoma. 
Immunotherapy. 2016;8:1245–1261.
 129. Tran E, Robbins PF, Lu YC, et  al. T-Cell transfer ther-
apy targeting mutant KRAS in cancer. N Engl J Med. 
2016;375:2255–2262.
 130. Le DT, Uram JN, Wang H, et  al. PD-1 blockade in 
tumors with mismatch-repair deficiency. N Engl J Med. 
2015;372:2509–2520.
 131. Millner LM, Strotman LN. The future of precision medicine in 
oncology. Clin Lab Med. 2016;36:557–573.
 132. Duzkale H, Shen J, McLaughlin H, et al. A systematic approach 
to assessing the clinical significance of genetic variants. Clin 
Genet. 2013;84:453–463.
 133. Meehan RS, Chen AP. New treatment option for ovarian cancer: 
PARP inhibitors. Gynecol Oncol Res Pract. 2016;3:3.
 134. Petrucelli N, Daly MB, Pal T. BRCA1- and BRCA2-associated 
hereditary breast and ovarian cancer. In: Pagon RA, Adam MP, 
1137Digestive Diseases and Sciences (2018) 63:1123–1138 
1 3
Ardinger HH, et al., eds. GeneReviews(R). Seattle, WA: Univer-
sity of Washington; 1993.
 135. Kohlmann W, Gruber SB. Lynch syndrome. In: Pagon RA, Adam 
MP, Ardinger HH, et al., eds. GeneReviews(R). Seattle, WA: Uni-
versity of Washington; 1993.
 136. Dong L, Wang W, Li A, et  al. Clinical next generation 
sequencing for precision medicine in cancer. Curr Genomics. 
2015;16:253–263.
 137. Mak IW, Evaniew N, Ghert M. Lost in translation: animal 
models and clinical trials in cancer treatment. Am J Transl Res. 
2014;6:114–118.
 138. Day CP, Merlino G, Van Dyke T. Preclinical mouse can-
cer models: a maze of opportunities and challenges. Cell. 
2015;163:39–53.
 139. Pereira JF, Awatade NT, Loureiro CA, et al. The third dimension: 
new developments in cell culture models for colorectal research. 
Cell Mol Life Sci. 2016;73:3971–3989.
 140. Huh D, Kim HJ, Fraser JP, et al. Microfabrication of human 
organs-on-chips. Nat Protoc. 2013;8:2135–2157.
 141. Nair R, Padhee S, Das T, et al. Three- and four-dimensional 
spheroid and fiss tumoroid cultures: platforms for drug discovery 
and development, and translational research. Crit Rev Ther Drug 
Carr Syst. 2017;34(3):185–208.
 142. Yoon YS, Kim JC. Recent applications of chemosensitivity 
tests for colorectal cancer treatment. World J Gastroenterol. 
2014;20:16398–16408.
 143. Hur H, Kim NK, Kim HG, et al. Adenosine triphosphate-based 
chemotherapy response assay-guided chemotherapy in unresect-
able colorectal liver metastasis. Br J Cancer. 2012;106:53–60.
 144. Kern DH, Weisenthal LM. Highly specific prediction of antineo-
plastic drug resistance with an in vitro assay using suprapharma-
cologic drug exposures. J Natl Cancer Inst. 1990;82:582–588.
 145. Mechetner E, Brunner N, Parker RJ. In vitro drug responses in 
primary and metastatic colorectal cancers. Scand J Gastroen-
terol. 2011;46:70–78.
 146. Fan CW, Fan HA, Hsu SH, et al. An in vitro short time-high dose 
drug exposure assay for predicting 5FU-resistance of colorectal 
cancer. Cancer Lett. 2004;214:181–188.
 147. Das T, Nair RR, Green R, et al. Actinomycin D down-regulates 
SOX2 expression and induces death in breast cancer stem cells. 
Anticancer Res. 2017;37:1655–1663.
 148. Girard YK, Wang C, Ravi S, et al. A 3D fibrous scaffold inducing 
tumoroids: a platform for anticancer drug development. PLoS 
ONE. 2013;8:e75345.
 149. Gluck S, de Snoo F, Peeters J, et al. Molecular subtyping of 
early-stage breast cancer identifies a group of patients who do 
not benefit from neoadjuvant chemotherapy. Breast Cancer Res 
Treat. 2013;139:759–767.
 150. Gluck S, McKenna EF Jr, Royce M. XeNA: capecitabine plus 
docetaxel, with or without trastuzumab, as preoperative therapy 
for early breast cancer. Int J Med Sci. 2008;5:341–346.
 151. Stachelscheid H, Wulf-Goldenberg A, Eckert K, et al. Tera-
toma formation of human embryonic stem cells in three-dimen-
sional perfusion culture bioreactors. J Tissue Eng Regen Med. 
2013;7:729–741.
 152. Chen J, Xia Q, Jiang B, et al. Prognostic value of cancer stem 
cell marker ALDH1 expression in colorectal cancer: a systematic 
review and meta-analysis. PLoS ONE. 2015;10:e0145164.
 153. Iinuma H, Watanabe T, Mimori K, et al. Clinical significance 
of circulating tumor cells, including cancer stem-like cells, 
in peripheral blood for recurrence and prognosis in patients 
with Dukes’ stage B and C colorectal cancer. J Clin Oncol. 
2011;29:1547–1555.
 154. Reya T, Morrison SJ, Clarke MF, et al. Stem cells, cancer, and 
cancer stem cells. Nature. 2001;414:105–111.
 155. Scatena R, Bottoni P, Pontoglio A, et al. Cancer stem cells: the 
development of new cancer therapeutics. Expert Opin Biol Ther. 
2011;11:875–892.
 156. Carmody L, Germain A, Morgan B, et al. Identification of a 
selective small-molecule inhibitor of breast cancer stem cells—
probe 3. In: Probe Reports from the NIH Molecular Libraries 
Program. Bethesda (MD); 2010.
 157. Carmody L, Germain A, Morgan B, et al. Identification of a 
selective small-molecule inhibitor of breast cancer stem cells—
probe 1. In: Probe Reports from the NIH Molecular Libraries 
Program. Bethesda, MD; 2010.
 158. Carmody LC, Germain A, Morgan B, et al. Identification of 
a Selective Small-Molecule Inhibitor of Breast Cancer Stem 
Cells—Probe 2. In: Probe Reports from the NIH Molecular 
Libraries Program. Bethesda, MD; 2010.
 159. Carmody LC, Germain AR, VerPlank L, et al. Phenotypic high-
throughput screening elucidates target pathway in breast cancer 
stem cell-like cells. J Biomol Screen. 2012;17:1204–1210.
 160. Germain AR, Carmody LC, Nag PP, et al. Cinnamides as selec-
tive small-molecule inhibitors of a cellular model of breast can-
cer stem cells. Bioorg Med Chem Lett. 2013;23:1834–1838.
 161. Hirano K, Sasaki N, Ichimiya T, et al. 3-O-sulfated heparan sul-
fate recognized by the antibody HS4C3 contributes [corrected] to 
the differentiation of mouse embryonic stem cells via fas signal-
ing. PLoS ONE. 2012;7:e43440.
 162. Johnson CE, Crawford BE, Stavridis M, et al. Essential altera-
tions of heparan sulfate during the differentiation of embryonic 
stem cells to Sox1-enhanced green fluorescent protein-expressing 
neural progenitor cells. Stem Cells. 2007;25:1913–1923.
 163. Nairn AV, Kinoshita-Toyoda A, Toyoda H, et al. Glycomics of 
proteoglycan biosynthesis in murine embryonic stem cell dif-
ferentiation. J Proteome Res. 2007;6:4374–4387.
Affiliations
Shyam S. Mohapatra1,2,3,4  · Surinder K. Batra1,5 · Srinivas Bharadwaj3 · Michael Bouvet1,6,7 · Bard Cosman6,7 · 
Ajay Goel1,8,9 · Wilma Jogunoori10,11 · Michael J. Kelley1,12,13 · Lopa Mishra1,10,11 · Bibhuti Mishra10,11 · 
Subhra Mohapatra1,2,14 · Bhaumik Patel1,15 · Joseph R. Pisegna1,16,17 · Jean‑Pierre Raufman1,18 · Shuyun Rao10,11 · 
Hemant Roy19 · Maren Scheuner1,16,17 · Satish Singh1,20 · Gitanjali Vidyarthi2,3 · Jon White10,11
 Surinder K. Batra 
 sbatra@unmc.edu
 Michael Bouvet 
 mbouvet@ucsd.edu
 Bard Cosman 
 Bard.Cosman@va.gov
 Ajay Goel 
 Ajay.Goel@BSWHealth.org
1138 Digestive Diseases and Sciences (2018) 63:1123–1138
1 3
 Michael J. Kelley 
 kelleym@duke.edu
 Lopa Mishra 
 lmishra@email.gwu.edu
 Subhra Mohapatra 
 smohapa2@health.usf.edu
 Bhaumik Patel 
 Bhaumik.Patel@va.gov
 Joseph R. Pisegna 
 Joseph.Pisegna@va.gov
 Jean-Pierre Raufman 
 jraufman@som.umaryland.edu
 Hemant Roy 
 hkroy@bu.edu
 Maren Scheuner 
 Maren.Scheuner@va.gov
 Satish Singh 
 Satish.Singh@va.gov
 Gitanjali Vidyarthi 
 Gitanjali.Vidyarthi@va.gov
1 Department of Veterans Affairs Colorectal Cancer Cell-
genomics Consortium [VA4C], Tampa, FL, USA
2 James A. Haley Veterans Hospital, Tampa, FL, USA
3 Division of Translational Medicine, Department of Internal 
Medicine, Morsani College of Medicine, University of South 
Florida, Tampa, FL, USA
4 College of Pharmacy Graduate Programs, University 
of South Florida, Tampa, FL, USA
5 Department of Biochemistry and Molecular Biology, 
Fred and Pamela Buffett Cancer Center, Eppley Institute 
for Research in Cancer, University of Nebraska Medical 
Center, Omaha, NE, USA
6 VA San Diego Healthcare System, San Diego, CA, USA
7 Department of Surgery, University of California San Diego 
Moores Cancer Center, San Diego, CA, USA
8 Center for Gastrointestinal Research, Center for Translational 
Genomics and Oncology, Baylor Scott & White Research 
Institute, Dallas, TX, USA
9 Charles A. Sammons Cancer Center, Baylor University, 
Dallas, TX, USA
10 Washington DC VA Medical Center, Washington, DC, USA
11 Department of Surgery, Center for Translational Medicine, 
George Washington University, Washington, DC, USA
12 National Oncology Program Office, Specialty Care Services, 
Department of Veterans Affairs, Durham VA Medical Center, 
Durham, NC, USA
13 Department of Medicine, Duke University Medical Center, 
Durham, NC, USA
14 Department of Molecular Medicine, Morsani College 
of Medicine, University of South Florida, Tampa, FL, USA
15 Hunter Holmes McGuire VA Medical Center and Department 
of Internal Medicine, Virginia Commonwealth University 
School of Medicine, Richmond, VA, USA
16 Division of Gastroenterology and Human Genetics, VA 
Greater Los Angeles Healthcare System, Los Angeles, CA, 
USA
17 Department of Medicine, David Geffen School of Medicine 
at UCLA, Los Angeles, CA, USA
18 VA Maryland Health Care System, Department of Medicine, 
University of Maryland School of Medicine, Baltimore, MD, 
USA
19 Department of Medicine, Boston University School 
of Medicine, Boston, MA, USA
20 VA Boston Healthcare System and Department of Medicine, 
Boston University School of Medicine, Boston, MA, USA
